Pfizer (NYSE: PFE) director awarded 7,686 phantom stock units

Q: What did Pfizer (PFE) director Susan Desmond-Hellmann report on this Form 4?

She reported receiving a grant of 7,686.539 phantom stock units tied to Pfizer common stock. These units represent deferred director compensation and increase her total phantom unit holdings to 45,635.605 , reflecting routine non-employee director compensation rather than an open-market stock purchase or sale.

Q: What are the phantom stock units reported by Pfizer (PFE) in this filing?

Each phantom stock unit represents one phantom share of Pfizer common stock . They track the value of the stock but are part of a deferred compensation arrangement for non-employee directors, rather than actual shares acquired in the market at the time of the grant.

Q: How and when will Susan Desmond-Hellmann’s Pfizer phantom stock units be settled?

The phantom stock units will be settled in cash or common stock at the director’s election. Settlement occurs after her retirement from Pfizer’s Board of Directors , aligning payout timing with the completion of her board service under the company’s deferred compensation plan.

Q: What plan governs the phantom stock units granted to Pfizer (PFE) directors?

The units are granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors . This plan provides deferred compensation in the form of phantom stock units, rather than immediate cash or stock, for eligible outside members of Pfizer’s board.

Q: Does this Pfizer (PFE) Form 4 show an open-market stock purchase or sale?

No. The filing reflects a grant/award acquisition of phantom stock units as director compensation, coded as transaction type “A”. It does not involve an open-market buy or sell of Pfizer common shares by Susan Desmond-Hellmann on the reported date.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Desmond-Hellmann Susan reported acquisition or exercise transactions in this Form 4 filing.

Pfizer Inc. director Susan Desmond-Hellmann received a grant of phantom stock units as part of her deferred board compensation. On this Form 4, she was awarded 7,686.539 phantom stock units, each linked to one share of Pfizer common stock. Following the award, she holds 45,635.605 phantom stock units in total. These units are granted under Pfizer’s Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors and will be settled in cash or common stock, at her election, after she retires from the board.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Desmond-Hellmann Susan

Role null

Type	Security	Shares	Price	Value
Grant/Award	Phantom Stock Units	7,686.539	$26.67	$205K

Holdings After Transaction: Phantom Stock Units — 45,635.605 shares (Direct, null)

Footnotes (1)

Each unit represents one phantom share of common stock. Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors.

Key Figures

Phantom stock units granted: 7,686.539 units Price per phantom unit: $26.6700 per unit Total phantom units after grant: 45,635.605 units +2 more

5 metrics

Phantom stock units granted 7,686.539 units Grant on 2026-04-23 as director compensation

Price per phantom unit $26.6700 per unit Reference price used for the reported grant

Total phantom units after grant 45,635.605 units Director’s phantom stock unit balance following the transaction

Underlying security 7,686.539 shares Underlying Pfizer common stock linked to phantom units granted

Conversion/exercise price $0.0000 Phantom stock units under deferred compensation plan

Key Terms

Phantom Stock Units, Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors, deferred director's compensation

3 terms

Phantom Stock Units financial

"Each unit represents one phantom share of common stock."

Phantom stock units are company promises that pay a cash or stock-equivalent award tied to the firm’s share price or value growth, but they do not issue actual shares. Think of them as a bonus check that moves with the stock like a mirror rather than handing over an ownership slice. Investors care because these awards can affect a company’s future cash obligations, executive incentives and reported expenses without causing share dilution.

Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors financial

"Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors."

deferred director's compensation financial

"These units represent deferred director's compensation that are settled in cash or common stock at the director's election"

Form 4 Insider Transactions: What Each Field Means →

04/27/2026 - 06:37 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Desmond-Hellmann Susan

(Last)

(First)

(Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK

10001-2192

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Phantom Stock Units	⁽¹⁾	04/23/2026		A		7,686.539⁽²⁾		⁽³⁾	⁽³⁾	Common Stock	7,686.539	$26.67	45,635.605	D

Explanation of Responses:

1. Each unit represents one phantom share of common stock.

2. Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.

3. These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors.

	/s/ Shanice A. Reid, by power of atty., for Susan Desmond- Hellmann	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Pfizer (PFE) director Susan Desmond-Hellmann report on this Form 4?

She reported receiving a grant of 7,686.539 phantom stock units tied to Pfizer common stock. These units represent deferred director compensation and increase her total phantom unit holdings to 45,635.605, reflecting routine non-employee director compensation rather than an open-market stock purchase or sale.

What are the phantom stock units reported by Pfizer (PFE) in this filing?

Each phantom stock unit represents one phantom share of Pfizer common stock. They track the value of the stock but are part of a deferred compensation arrangement for non-employee directors, rather than actual shares acquired in the market at the time of the grant.

How and when will Susan Desmond-Hellmann’s Pfizer phantom stock units be settled?

The phantom stock units will be settled in cash or common stock at the director’s election. Settlement occurs after her retirement from Pfizer’s Board of Directors, aligning payout timing with the completion of her board service under the company’s deferred compensation plan.

What plan governs the phantom stock units granted to Pfizer (PFE) directors?

The units are granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. This plan provides deferred compensation in the form of phantom stock units, rather than immediate cash or stock, for eligible outside members of Pfizer’s board.

Does this Pfizer (PFE) Form 4 show an open-market stock purchase or sale?

No. The filing reflects a grant/award acquisition of phantom stock units as director compensation, coded as transaction type “A”. It does not involve an open-market buy or sell of Pfizer common shares by Susan Desmond-Hellmann on the reported date.